No Cover Image

Journal article 355 views 22 downloads

Cardiovascular function in people with cystic fibrosis on Elexacaftor/Tezacaftor/Ivacaftor: A cross-sectional, observational, single-centre study

Lauren J Clayton Orcid Logo, Anthony I Shepherd Orcid Logo, Jo Corbett Orcid Logo, Maria Perissiou Orcid Logo, Gary Connett, Julian Legg, Mark Allenby Orcid Logo, Thomas Daniels Orcid Logo, Don S Urquhart Orcid Logo, Kelly Mackintosh Orcid Logo, Melitta McNarry Orcid Logo, Zoe L Saynor Orcid Logo

Journal of Cystic Fibrosis, Volume: 24, Issue: 4, Pages: 801 - 808

Swansea University Authors: Kelly Mackintosh Orcid Logo, Melitta McNarry Orcid Logo

  • 69150.VOR.pdf

    PDF | Version of Record

    © 2025 The Author(s). This is an open access article distributed under the terms of the Creative Commons CC-BY license.

    Download (598.85KB)

Check full text

DOI (Published version): 10.1016/j.jcf.2025.02.001

Abstract

Background: Cystic fibrosis (CF) has been associated with impaired cardiovascular and endothelial function. CF transmembrane conductance regulator (CFTR) modulator therapy, most recently, Elexacaftor/Tezacaftor/Ivacaftor (ETI) has led to improved CFTR function and life expectancy, however, the risin...

Full description

Published in: Journal of Cystic Fibrosis
ISSN: 1569-1993 1873-5010
Published: Elsevier BV 2025
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa69150
Abstract: Background: Cystic fibrosis (CF) has been associated with impaired cardiovascular and endothelial function. CF transmembrane conductance regulator (CFTR) modulator therapy, most recently, Elexacaftor/Tezacaftor/Ivacaftor (ETI) has led to improved CFTR function and life expectancy, however, the rising prevalence of obesity in adults is concerning. This study assessed the micro- and macro-vascular endothelial function, cardiovascular disease (CVD) risk factors, and physical activity (PA) profiles in people with CF (pwCF) on ETI compared to healthy matched controls. Methods: In 15 pwCF and 15 age- and sex-matched controls, microvascular endothelial function (via transdermal delivery of insulin [INS] and acetylcholine [ACh] on the forearm), macrovascular endothelial function (via flow-mediated dilation [FMD] of the brachial artery), central haemodynamic parameters, including heart rate (HR), stroke volume index (SVi) and cardiac output index (Q̇I) (via thoracic impedance cardiography), body mass index (BMI), blood pressure (BP), and accelerometer-assessed PA, were measured. Results: There were no differences in INS or FMD-mediated vasodilation between the groups (P>0.05). However, a reduced vasodilatory response was evident in pwCF following ACh-mediated vasodilation (P=0.01) and FMD normalised for shear rate (P=0.03). No differences in resting HR, SVi, Q̇I, BP, BMI or PA were found (P>0.05). Conclusion: This study demonstrated reduced micro- and macrovascular function in pwCF. This dysfunction may have potential health implications, particularly regarding long-term cardiovascular risk and further longitudinal assessments are warranted.
Keywords: Cardiovascular; CFTR modulator therapy; Endothelial function; Flow-mediated dilation; Iontophoresis; Physical activity
College: Faculty of Science and Engineering
Funders: This study was funded by the Cystic Fibrosis Warriors Charity (Charity No 1178063).
Issue: 4
Start Page: 801
End Page: 808

Similar Items